Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Rhea-AI Summary

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for CNS, inflammatory and cardiometabolic diseases, announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate update through a pre-recorded presentation, which will be available on-demand to registered conference attendees starting Monday, June 16, 2025, at 7:00 a.m. ET. The conference is scheduled for June 16-17, 2025, and will be held in a virtual format.

CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 6^th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.

H.C. Wainwright 6^th Annual Neuro Perspectives Hybrid Conference
Format: Corporate update
Date/Time: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ET for registered conference attendees
Location: Virtual
Registration Link: Click Here

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

When is Reviva Pharmaceuticals (RVPH) presenting at the H.C. Wainwright Neuro Conference 2025?

Reviva's pre-recorded presentation will be available on-demand starting Monday, June 16, 2025, at 7:00 a.m. ET.

Who will be presenting for Reviva Pharmaceuticals at the H.C. Wainwright conference?

Laxminarayan Bhat, Ph.D., who is the Founder, President, and CEO of Reviva, will deliver the corporate update presentation.

What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?

Reviva focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases.

Is the H.C. Wainwright Neuro Perspectives Conference 2025 virtual or in-person?

The conference is a hybrid event, with Reviva's presentation being available virtually for registered attendees.